Lynx1-Capital-Management-Lp

Filing Details

13F-HR2025-03-31
Report Date
2025-03-31
Filing Date
2025-05-15
Total Holdings
14
Total Value
279234734
Accession Number
0001892688-25-000120
Form Type
13F-HR
Manager Name
Lynx1-Capital-Management-Lp
Data Enrichment
93% identified
13 identified1 unidentified

Holdings

14 positions
Manager:
Search and click to pin securities to the top
GH Research PLC
Shares:6.4M
Value:$71.1M
Merus N.V.
Shares:1.6M
Value:$66.0M
Protagonist Therapeutics, Inc
Shares:733.0K
Value:$35.4M
Stoke Therapeutics, Inc.
Shares:5.3M
Value:$35.2M
Cullinan Therapeutics, Inc.
Shares:3.2M
Value:$24.3M
Allogene Therapeutics, Inc.
Shares:11.1M
Value:$16.1M
C4 Therapeutics, Inc.
Shares:7.1M
Value:$11.4M
TScan Therapeutics, Inc.
Shares:5.4M
Value:$7.4M
PRECISION BIOSCIENCES INC
Shares:766.1K
Value:$3.7M
iBio, Inc.
Shares:862.3K
Value:$3.5M
Passage BIO, Inc.
Shares:9.3M
Value:$3.3M
Upstream Bio, Inc.
Shares:219.2K
Value:$1.3M
64136E102
Shares:45.8K
Value:$263.8K
Design Therapeutics, Inc.
Shares:66.0K
Value:$254.6K